Clinical Grip Training and Assessment Tool for Rheumatoid Arthritis

BAM Innovation和Optima Design将共同设计一种用于类风湿性关节炎（RA）的破坏性治疗和监测设备：Grip-RA。迫切需要替代方法来支持患有这种无法治愈的自身免疫性疾病的患者，这种疾病影响全球2300万人，其中三分之一的RA患者在诊断后五年内停止工作，并且用于管理病情的生物药物极其昂贵，该项目将设计一种创新的设备，便于患者参与，监测和病情管理。Grip-RA被设想为具有嵌入式传感器的物理“压力球”式界面，提供黄金标准的物理康复益处，同时捕获丰富的客观和患者报告的数据，以支持患者和临床医生更好的病情管理。其简单的界面将是直观的，以客户为中心的，可访问的，包括那些严重的RA。患者和临床医生都呼吁非智能手机为基础的方法，这有臭名昭著的病人依从性差。BAM的两个主任有一个人的兴趣，在RA与深入的条件具体的知识，特别是考虑到病人的角度。这个项目将建立在这方面的知识，设计一个新的一类康复工具，连接病人和临床实践的时尚，提供更明确的好处给用户。我们的主要目的是研究Grip-RA产品的商业拉动和设计可行性。我们将深入研究潜在市场。与潜在客户的密切接触将使我们了解他们的需求，并为设计过程提供信息。这将使我们能够生产产品设计（CAD +模型）由客户需求驱动（例如，临床医生/信托机构和制药公司），并由巴斯风湿病研究所慈善机构促进的RA患者共同开发/评估。BAM将通过能够进入英国/全球RA市场而受益，全球类风湿关节炎药物市场是重要的，预计到2027年将达到630亿美元，并提供多种机会来发展部署我们技术的合作伙伴关系。例如，我们提议与一家领先的临床家庭护理/专科药房供应商建立探索性合作伙伴关系。主要的外部受益者是获得更好患者数据的临床医生和患者本人，他们将获得更好的康复/治疗，减少痛苦，并支持更好地参与社会和经济。

BAM Innovation and Optima Design will co-design a disruptive treatment and monitoring device for rheumatoid arthritis (RA): Grip-RA.There is a desperate need for alternative approaches to support patients with this incurable autoimmune disease affecting \>23m people worldwide, with one-third of people with RA stopping working within five years of diagnosis and the biologic drugs used to manage the condition being extremely expensive, with dosages needing tailoring based on changes in disease activity.This project will design an innovative device which facilitates patient engagement, monitoring and condition management. Grip-RA is envisaged as a physical "stress-ball" style interface, with embedded sensors, offering gold-standard physical rehabilitation benefits, whilst capturing rich objective and patient-reported data to support better condition management for patients and clinicians. Its simple interface will be intuitive, customer-focused, and accessible, including to those with severe RA. Patients and clinicians are calling out for non-smartphone based approaches, which have notoriously poor patient adherence.BAMs two Directors have a personal interest in RA with deep condition specific knowledge, particularly considering the patient perspective.This project will build on this knowledge to design a new class of rehabilitative tool that links patient and clinical practice in a fashion which offers far clearer benefit to the user.Our main objectives are to research both the commercial pull and design feasibility of the Grip-RA product. We will research potential markets in depth. Close engagement with potential clients will inform us about their needs and inform the design process. This will allow us to produce product designs (CAD + model) driven by customer needs (e.g. clinicians/trusts and pharma) and co-developed/assessed by RA sufferers facilitated by the Bath Institute of Rheumatic Diseases charity.BAM will benefit through being able to enter UK/global RA markets, The global rheumatoid arthritis drugs market is significant, projected to reach $63bn by 2027 and presents multiple opportunities to develop partnerships deploying our technology. An example is our proposed exploratory partnership with a leading clinical home-care/specialist pharmacy provider.Key external beneficiaries are clinicians receiving better patient data and patients themselves, who will receive better rehabilitation/treatment reducing suffering and supporting better engagement with society and the economy.